Microsoft co-founder Paul Allen relaunched a wide-ranging patent lawsuit against Apple, Google, Facebook and others with specific allegations that the companies are illegally using technology owned by his company. Get the full story »
Inside these posts: Patent
Visit our Filed page for categories. To browse by specific topic, see our Inside page. For a list of companies covered on this site, visit our Companies page.
Microsoft sues Motorola over Xbox patent issue
Microsoft Corp stepped up its legal battle with Motorola Inc on Tuesday, as the software company accused the phone maker of charging excessive royalties on network technology used in Microsoft’s Xbox game system. Get the full story »
WMS sues Bally Gaming over patent infringement
Waukegan-based slot machine maker WMS Industries Inc. said its gaming unit filed a patent infringement lawsuit against a unit of smaller rival Bally Technologies Inc., seeking injunctive relief and unspecified damages.
Several of Bally Gaming’s products, including its Cash Spin product, infringe WMS patents covering WMS’ Transmissive Reels gaming concept and technology, WMS said in a statement. Get the full story »
FDA tells of generic competition for Latisse
An unnamed drug maker has applied for U.S. regulatory approval to sell a generic version of Allergan Inc.’s eyelash-enhancing drug Latisse before its patent protection expires.
Latisse, approved in late 2008 with $73.3 million in sales last year, has market exclusivity until late 2011. But the Food and Drug Administration disclosed last week that a company filed an application in May to market a copycat version by challenging Allergan’s patent for the drug. The FDA didn’t identify the applicant of the generic drug. Get the full story »
Judge upholds Crestor patent
A U.S. judge handed AstraZeneca Plc a huge victory Tuesday, finding that the patent on its multibillion-dollar cholesterol fighter Crestor is valid, sending the the British drugmaker’s shares up 9 percent.
Judge Joseph Farnan, of the U.S. District Court in Delaware, ruled that generic drugmakers who challenged the patent failed to prove it was invalid because it was an obvious invention. Get the full story »
